Association of BRCA alteration (alt) type with real-world (RW) outcomes to PARP inhibitors (PARPi) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Antonarakis, Emmanuel S.
Madison, Russell
Snider, Jeremy
Snow, Tamara
Sokol, Ethan
Chung, Jon
McCusker, Margaret Elizabeth
Singal, Gaurav
Alexander, Brian Michael
Castellanos, Emily
Venstrom, Jeffrey
Schrock, Alexa Betzig
Ross, Jeffrey S.
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Fdn Med Inc, Cambridge, MA USA
[3] Flatiron Hlth, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5527
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase I study of apalutamide (ARN) plus abiraterone acetate (AA), docetaxel (D) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Molina, A. M.
    Christos, P. J.
    Whang, Y.
    Nordquist, L.
    Hackett, A. L.
    Beltran, H.
    Faltas, B.
    Nanus, D.
    Giannakakou, P.
    Tagawa, S. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [42] Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
    Yu, Evan Y.
    Massard, Christophe
    Retz, Margitta
    Tafreshi, Ali
    Carles Galceran, Joan
    Hammerer, Peter
    Fong, Peter C. C.
    Shore, Neal D.
    Joshua, Anthony
    Linch, Mark David
    Gurney, Howard
    Romano, Emanuela
    Augustin, Marinela
    Piulats, Josep M.
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [43] Abiraterone in metastatic castrate resistant prostate cancer: outcome and tolerance in real-world setting
    Lim, J.
    Shariff, N.
    Saad, M.
    Alip, A.
    Ong, T.
    Lechmiannandan, S.
    Ahmayuddin, F.
    Mathew, A.
    Tze, F. C. L.
    BJU INTERNATIONAL, 2017, 120 : 10 - 11
  • [44] Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer
    Shivji, Alisha
    Ali, Raafi
    North, Scott
    Sawyer, Michael
    Ghosh, Sunita
    Chambers, Carole
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (06) : 1293 - 1300
  • [45] Genomic/genetic testing patterns for patients with metastatic castrate-resistant prostate cancer: Results from a real-world study in the United States.
    Leith, Andrea
    Ribbands, Amanda
    Last, Matthew
    Gayle, Alicia
    Payne, Sarah
    McCrea, Charles
    Yang, Lingfeng
    Burgents, Joseph E.
    Ghate, Sameer
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [46] Comparison of survival of African-American (AA) patients (pts) in docetaxel (D)-based combination therapies in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Ning, Yang-Min
    Theoret, Marc Robert
    Arlen, Philip M.
    Parnes, Howard L.
    Ojemuyiwa, Michelle A.
    Strauss, Julius
    Dawson, Nancy Ann
    McLeod, David G.
    Harold, Nancy
    Couvillon, Anna
    Cordes, Lisa M.
    Chen, Clara
    Steinberg, Seth M.
    Sissung, Tristan M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [47] Real-world outcome with abiraterone acetate plus prednisone in Asian men with metastatic castrate-resistant prostate cancer: The Singapore experience
    Chan, Johan
    Yap, Shi Yin
    Fong, Yian Ching
    Lim, Heng Chi
    Toh, Chee Keong
    Ng, Quan Sing
    Rajasekaran, Tanujaa
    Chua, Melvin
    Lee, Lui Shiong
    Wong, Alvin
    Loh, Ker Yun
    Chow, Marcus
    Wong, Siew Wei
    Kanesvaran, Ravindran
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (01) : 75 - 79
  • [48] Trends in prescribing preferences (PPrefs) of US-based oncologists for patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) following docetaxel (DO).
    Ryan, Charles J.
    Kim, Won
    Buettner, Arden
    Britton, Susan Lynne
    Lankford, Maria L.
    Neely, Doug B.
    Green, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [49] A real-world retrospective analysis of the management of metastatic castrate-resistant prostate cancer in Ontario, Canada from 2010-2018
    Moldaver, Daniel M.
    Hassan, Shazia
    Seung, Soo Jin
    Edwin, Jonathan
    Clouthier, Derek L.
    Vera-Badillo, Francisco E.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (03) : 146.e13 - 146.e22
  • [50] Plasma Cell-Free DNA (cfDNA) Concentration and Outcomes in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Patients Treated with Androgen Receptor Signalling Inhibitors (ARSIs)
    Fettke, Heidi
    Kwan, Edmond
    Mant, Andrew
    Docanto, Maria
    Bukczynska, Patricia
    To, Sarah
    Waltham, Mark
    Ng, Nicole
    Parente, Phillip
    Pezaro, Carmel
    Azad, Arun
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 29 - 29
12345